Michael R. Liebling is a Torrance, California based male rheumatologist who is specialized in Rheumatology. Active license number of Michael R. Liebling for Rheumatology is G28393 in California. Michael R. Liebling treat joint disease similar to orthopedists but do not perform surgeries. He diagnose and treat diseases of joints, muscle, bones and tendons which includes arthritis, back pain, muscle strains, common athletic injuries and 'collagen' diseases.
Complete Profile:
Michael R. Liebling speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1386691376
NPI Enumeration Date:
27 May, 2006
NPI Last Update On:
09 Jul, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Michael R. Liebling are as mentioned below.
License Number
Specialization
State
Status
G28393
Rheumatologist
California
Primary
Other Medical Identifiers:
Other legacy medical identifiers associated with Michael R. Liebling such as Medicaid, Medicare PIN, NSC, UPIN etc. are mentioned as below.
Identifier
Type
State
Issuer
00G283930
Medicaid
California
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
21840 Normandie Ave, Ste. 700 Torrance, California
Zip:
90502-2047
Phone Number:
310-222-5101
Fax Number:
310-320-5463
Patients can reach Michael R. Liebling at 21840 Normandie Ave, Ste. 700, Torrance, California or can call to book an appointment on 310-222-5101. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.